Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.

AstraZeneca lupus drug meets main goal in study

AstraZeneca lupus drug meets main goal in study
FILE PHOTO: Logo of AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid -
Brendan McDermid(Reuters)
Euronews logo
Text size Aa Aa

(Reuters) – AstraZeneca Plc <AZN.L> said on Thursday its experimental drug to treat moderate-to-severe lupus, anifrolumab, met its main goal in a late-stage study.

The drug showed a “statistically-significant” and “clinically-meaningful” reduction in the disease in patients with systemic lupus erythematosus, commonly known as SLE, the company said.

(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Sriraj Kalluvila)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.